Clinical Trial Update: 177Lu-LNC1011 in Patients with Metastatic Castration-resistant Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/Phase 2 trial update for the radiopharmaceutical 177Lu-LNC1011 in metastatic castration-resistant prostate cancer. The current trial status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• 177Lu-LNC1011

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 1, Phase 2 | Status: UNKNOWN